Executive Management
Shunee Yee
President & CEO
Ms. Shunee Yee, with over 25 years in the language industry, is the founder and CEO of CSOFT International. Recognized among Fortune’s Top 10 Most Powerful Women Entrepreneurs and CNN Money’s Top 25 Innovation disrupters, Ms. Yee has steered CSOFT’s rapid growth, establishing it as a leading translation company.
Beyond her business achievements, she actively supports educational and social causes, serving as a trustee at Dexter Southfield school and contributing to international programs at Johns Hopkins University. Notably, she co-chaired the Taste of Ginger diabetes education initiative in 2021 and 2022. Currently, she serves on the board of directors at Beth Israel Lahey Health’s Joslin Diabetes Center, demonstrating her commitment to Boston’s Life Sciences sector.
Vladimir (Vlado) Misik
VP Global Clinical Trial Strategy at CSOFT Health Sciences
Vladimir (Vlado) Misik brings more than 30 years of biomedical R&D experience into his role as VP of Global Clinical Trial Strategy at CSOFT Health Sciences.
After his MSc degree physics and biophysics, and a PhD in biophysics and pharmacology, he worked for several years as a research scientist in the fields of cardiology, at the School of Medicine at the George Washington University, and oncology, at the National Cancer Institute at the NIH in Bethesda. After his biomedical research scientist tenure, he moved into biopharma product development, including 15+ years at Quintiles/IQVIA in various senior executive roles including VP & Head of Central and Eastern Europe and MENA, and VP of Global Delivery Network. He also served as an executive board member and a CEO at SanaClis, a global full-service specialty CRO. He is a founder and co-founder of two companies providing services to the clinical research industry: LongTaal, a proprietary clinical trials informatics platform, and VIARES, a clinical research talent organization.
Vlado is an author of over 60 research articles and book chapters in peer-reviewed journals. His current research focus is global geographic trends in industry clinical trials. He serves as an editorial board member at Applied Clinical Research, Clinical Trials, and Regulatory Affairs journal, and is a member of the DIA Core Committee for Clinical Research.
Diego Di Leva
Vice President, Global Operations & Strategic Partnership
Originally from Italy, Diego Di Leva is the VP of Global Language Resources. In this role, Diego leads teams responsible for executing end-to-end project management and supply chain strategy.
He joined CSOFT as an Italian QA Specialist/Translator, position that he covered for five years after which he has started to cover more managerial and operational roles. Prior to joining CSOFT, Diego worked as a Tech Consultant for two years at a leading global mobile company.
CJ Li
Scientific Advisor, CSOFT Health Sciences
Li Chenjian is a principal investigator at the IDG McGovern Institute for Brain Research and Associate Dean of the School of Life Sciences at Peking University. His research in neuroscience and drug development has led to significant insights into the mechanisms of neurodegenerative diseases.
Bruce Wang
Chief Strategist, China Market Access
With more than 14 years of experience working with international pharmaceutical programs in anti-infective, cardiovascular, endocrine, and nutritional products at companies including Xi‘an Janssen, Novartis Pharmaceuticals, and Mead Johnson (China), Dr. Wang has participated in Asian market registration, clinical research, and market access projects of many important domestic drug varieties.
These projects included: driving the marketing of Zhejiang Whiteson’s Latamoxef (a broad- spectrum beta-lactam antibiotic); facilitating the rapid sales growth (over three years) of Hainan Tianhuang and its nearly 1 billion RMB in revenues after the overall acquisition; assisting Henan Shuaiguang as it became the second company in China to market Clopidogrel there; participating in the formulation of different dose strengths to achieve a greater market success; and indirectly helping Lepu Medical and Gloria Pharmaceuticals to achieve their goals.
Dr. Wang entered the field of translational research in 2013. He headed the Foshan Industrial Technology Research Institute of the Chinese Academy of Sciences’ pharmaceutical project and established strong commercialization partnerships with the Chinese Academy of Sciences and Peking University.
Dr. Wang holds a degree in Pharmacy from the Peking University Health Science Center and was Vice Chairman of the Student Union at the Center.